PR Newswire

NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia

Written by PR Newswire

SHANGHAI and LEXINGTON, Mass. , May 8, 2024 /PRNewswire/ -- NeuShen Therapeutics (the "Company"), a clinical-stage global biotechnology company dedicated to pioneering treatments for neurological and psychiatric disorders, today announced the dosing of the first healthy volunteer in Australia in the Phase I first-in-human clinical trial of...

ACCC cracks down on misleading environmental claims
The nation’s consumer watchdog is cracking down on businesses making misleading environmental claims and fake online reviews by launching two internet sweeps to identify companies acting in bad faith. BusinessNewsAustralia reports…
the customer reviews most likely to influence purchasing decisions
Consumer reviews have changed many an industry.ShutterstockWhether you are booking a hotel room, choosing a restaurant, deciding on what movie to see or buying any number of things, it is…
the pros and cons of a pet-friendly office
ShutterstockFor you and your pooch a pet-friendly workplace may seem a no-brainer.More of us are facing pet separation anxiety than ever before. Dog ownership surged with pandemic lockdowns and working…
The cost-of-living crisis is hitting hard. Here are 3 ways to soften the blow
ShutterstockAs our wallets feel the strain from the cost-of-living crisis, many of us are looking for ways to soften the blow.While everyone’s circumstances are different, and ideally you should seek…